The 20 linked references in paper E. KROPACHEVA S., O. ZEMLYANSKAYA A., A. DOBROVOLSKY B., E. PANCHENKO P., Е. КРОПАЧЕВА С., О. ЗЕМЛЯНСКАЯ А., А. ДОБРОВОЛЬСКИЙ Б., Е. ПАНЧЕНКО П. (2017) “ЭФФЕКТИВНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ ВАРФАРИНОМ: ВЛИЯНИЕ НА ЧАСТОТУ ИШЕМИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ И КЛИНИЧЕСКИЕ ПРЕДИКТОРЫ ИХ РАЗВИТИЯ (результаты проспективного 10-летнего наблюдения) // THE EFFICACY OF LONG-TERM WARFARIN THERAPY: THE IMPACT ON THE INCIDENCE OF ISCHEMIC CEREBROVASCULAR DISORDERS AND CLINICAL PREDICTORS OF DEVELOPING SUCH DISORDERS. (Results of a prospective 10-year follow-up study)” / spz:neicon:aterotromboz:y:2017:i:2:p:115-130

  1. ESC Guidelines for the management of atrial fibrillation 2016. DOI: http://dx.doi.org/10.1093/eurheartj/ehw210 eh w210 First published online: 27 August 2016.
  2. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e637S–68S. doi: 10.1378/chest.11-2306. pmid:22315274.
  3. Arihiro S, Todo K, Koga M et al. Three-month riskbenefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke, 2016 Jul, 11(5): 565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
  4. Ba_aran Е, Dogan V, Biteker M et al. Guideline-adherent therapy for stroke prevention in atrial fibrillation in different health care settings: Results from RAMSES study. Eur J Intern Med, 2017 May, 40: 50-55. doi: 10.1016/j.ejim.2017.02.011. Epub 2017 Feb 24.
  5. Sullivan RM, Zhang J, Zamba G et al. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol,2012 Dec 15, 110(12): 1799-802. doi: 10.1016/j.amjcard.2012.08.014. Epub 2012 Sep 18.
  6. 1161/JAHA.116.004069. 10. Schwammenthal Y, Bornstein N et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey. Am J Cardiol, 2010 Feb 1, 105(3): 411-6. doi: 10.1016/j.amjcard.2009.09.050. Epub 2009 Dec 22.
  7. Connolly SJ, Ezekowitz MD, Salim Yusuf et al and the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2009, 361: 1139-1151. DOI: 10.1056/NEJMoa090556123.
  8. Goto S, Zhu J, Liu L et al. ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J, 2014 Sep, 168(3): 303-9. doi: 10.1016/j.ahj.2014.06.005.
  9. Irie F, Kamouchi M, Hata J et al. FSR Investigators. Sex differences in short-term outcomes after acute ischemic stroke: the FUKUOKA stroke registry. Stroke, 2015 Feb, 46(2): 471-476. doi: 10.1161/STROKE AHA.114.006739. Epub 2014 Dec 30.
  10. Abdul-Rahim AH, Fulton RL, Frank B et al. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol, 2015 Jul, 22(7): 1048-1055. doi: 10.1111/ene.12577. Epub 2014 Oct 16.
  11. Paciaroni M, Agnelli G, Falocci N et al. Early Recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: The RAF Study. Stroke, 2015 Aug, 46(8): 2175-2182. doi: 10.1161/STROKEAHA.115.008891. Epub 2015 Jun 30.
  12. Albertsen IE, Rasmussen LH, Overvad TF et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke, 2013 May, 44(5): 13291336. doi: 10.1161/STROKEAHA.113.000883. Epub 2013 Mar 12.
  13. Alonso A, Knopman DS, Gottesman RF et al. Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). J Am Heart Assoc, 2017 Jul 24, 6(7): pii: e006014. doi: 10.1161/JAHA.117.006014.
  14. Liao JN, Chao TF, Liu CJ et al. Risk and prediction of dementia in patients with atrial fibrillation—a nationwide population-based cohort study. Int J Cardiol, 2015 Nov 15, 199: 25-30. doi: 10.1016/j.ijcard.2015.06.170. Epub 2015 Jul 6.
  15. Ball J, Carrington MJ, Stewart S, SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart, 2013 Apr, 99(8): 542-547. doi: 10.1136/heartjnl-2012-303182. Epub, 2013 Jan 12.
  16. Eggermont LH, de Boer K, Muller M et al. Cardiac disease and cognitive impairment: a systematic review. Heart, 2012 Sep, 98(18): 1334-1340. doi: 10.1136/heartjnl-2012-301682. Epub 2012 Jun 11.
  17. Gorzelak-Pabi_ P, Zyzak S, Krewko _, Broncel M. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment. Pol Arch Med Wewn, 2016 Aug 9, 126(7-8): 494-501. doi: 10.20452/pamw.3475. Epub 2016 Aug 9.
  18. Jacobs V, Woller SC, Stevens S et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 2014 Dec, 11(12): 2206-2213. doi: 10.1016/j.hrthm.2014.08.013. Epub 2014 Aug 9.
  19. Кропачева Е.С., Панченко Е.П. Безопасность длительной терапии варфарином: алгоритмы лечения и факторы, определяющие стабильность антикоагуляции. Клиницист, 2007, 4: 48-55.
  20. Palareti G, Antonucci E, Migliaccio L et al. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med, 2017 May 13. doi: 10.1007/s11739-017-1678-9. [Epub ahead of print].